Utility of atherosclerosis imaging in the evaluation of high-density lipoprotein-raising therapies

Current Atherosclerosis Reports

Volumn 13, Issue 3, 2011, Pages 277-284

  Duivenvoorden, Raphaël ^a,b   Fayad, Zahi A ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

18F fluordeoxyglucose positron emission tomography; Atherosclerosis; Endothelial function; Flow mediated vasodilatation; High density lipoprotein cholesterol; Inflammation; Intima media thickness; Magnetic resonance imaging; Ultrasound

Indexed keywords

DALCETRAPIB; FLUORODEOXYGLUCOSE F 18; GLIMEPIRIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PIOGLITAZONE; PLACEBO; TORCETRAPIB;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; B SCAN; BLOOD PRESSURE; BLOOD VESSEL WALL; BRACHIAL ARTERY; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DRUG MONITORING; FUNCTIONAL ASSESSMENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; ISCHEMIC HEART DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; REVIEW; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK;

CAROTID ARTERIES; CHOLESTEROL, HDL; DRUG MONITORING; ENDOTHELIUM, VASCULAR; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; MAGNETIC RESONANCE IMAGING; MICROSCOPY, ACOUSTIC; PHARMACOLOGY, CLINICAL; PLAQUE, ATHEROSCLEROTIC; POSITRON-EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUNICA INTIMA; VASODILATION;

EID: 79955923280     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-011-0176-1     Document Type: Review

References (50)

1. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8-15.
2. Besler C, Heinrich K, Riwanto M, et al. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. Curr Pharm Des. 2010;16:1480-93.
3. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620-30. (Pubitemid 46631671)
4. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459-67. (Pubitemid 46184197)
5. Paramsothy P, Knopp RH, Bertoni AG, et al. Association of combinations of lipid parameters with carotid intima-media thickness and coronary artery calcium in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2010;56:1034-41.
6. Chambless LE, Folsom AR, Davis V, et al. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol. 2002;155:38-47.
7. Hovingh GK, de Groot E, van der Steeg W, Boekholdt SM, Hutten BA, Kuivenhoven JA, et al. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol. 2005;16(2):139-45. (Pubitemid 40515887)
8. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial biology for the investigation of the treatment effect of reducing cholesterol (ARBITER) 2. A double-blind, placebo controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-7.
9. Taylor AJ, Lee HJ, Sullenberg LE. The effect of 24 months of combination statin and extended-release niacin on carotid intimamedia thickness:ARBITER 3. Curr Med Res Opin. 2006;22:2243-50. (Pubitemid 44789989)
10. Taylor AJ, Villines TC, Stanek EJ, et al.: Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122. This ultrasound CIMT study shows that raising HDL-C with niacin is more effective than lowering LDL-C with ezetimibe for decreasing atherosclerosis progression.
11. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of cholestipol-niacin therapy on common carotid artery. Two- and four-year reduction in intima-media thickness measured by ultrasound. Circulation. 1993;88:20-8.
12. Mack WJ, Selzer RH, Hodis HN, et al. One-year reduction and longitudinal analyses of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke. 1993;24:1779-83. (Pubitemid 23352702)
13. Bots ML, Visseren FL, Evans GW, et al. RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370:153-60.
14. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-22. (Pubitemid 350146106)
15. Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008;118:2515-22.
16. Yuan C, Beach KW, Smith Jr LH, et al. Measurement of atherosclerotic carotid plaque size in vivo using high resolution magnetic resonance imaging. Circulation. 1998;98:2666-71. (Pubitemid 28564000)
17. Duivenvoorden R, de Groot E, Elsen BM, et al. In vivo quantification of carotid artery wall dimensions: 3.0-Tesla MRI versus B-mode ultrasound imaging. Circ Cardiovasc Imaging. 2009;2:235-42.
18. Li F, Yarnykh VL, Hatsukami TS, et al. Scan-rescan reproducibility of carotid atherosclerotic plaque morphology and tissue composition measurements using multicontrast MRI at 3 T. J Magn Reson Imaging. 2010;31:168-76.
19. Underhill HR, Yuan C, Yarnykh VL, et al. Predictors of surface disruption with MR imaging in asymptomatic carotid artery stenosis. Am J Neuroradiol. 2009;31:487-93.
20. Takaya N, Yuan C, Chu B, et al. Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: a prospective assessment with MRI: initial results. Stroke. 2006;37:818-23. (Pubitemid 43731915)
21. Altaf N, Daniels L, Morgan PS, et al. Detection of intraplaque hemorrhage by magnetic resonance imaging in symptomatic patients with mild to moderate carotid stenosis predicts recurrent neurological events. J Vasc Surg. 2008;47:337-42.
22. Parmar JP, Rogers WJ, Mugler JP 3 rd, et al.: Magnetic resonance imaging of carotid atherosclerotic plaque in clinically suspected acute transient ischemic attack and acute ischemic stroke. Circulation 2010, 122:2031-2038. This MRI study shows that American Heart Association plaque type 6 is highly predictive of TIA/stroke at the moment of onset of symptoms.
23. http://www.hrpinitiative.com
24. Holleboom AG, Duivenvoorden R, van den Bogaard B, et al.: Patients with Low Plasma High Density Lipoprotein-Cholesterol due to Mutations in the Gene Encoding for Lecithin: Cholesterol Acyl Transferase have Increased Atherosclerosis: A 3.0 Tesla MRI Study. Circulation 2010, 122:A17773. This MRI study shows that carriers of LCAT gene mutations have increased atherosclerosis.
25. Wagenknecht L, Wasserman B, Chambless L, et al. Correlates of carotid plaque presence and composition as measured by MRI: the Atherosclerosis Risk in Communities Study. Circ Cardiovasc Imaging. 2009;2:314-22.
26. Wasserman BA, Sharrett AR, Lai S, et al. Risk factor associations with the presence of a lipid core in carotid plaque of asymptomatic individuals using high-resolution MRI: the multi-ethnic study of atherosclerosis (MESA). Stroke. 2008;39:329-35. (Pubitemid 351619451)
27. Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol. 2009;54:1787-94.
28. Zhao XQ, Phan BA, Chu B, et al. Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study. Am Heart J. 2007;154:239-46. (Pubitemid 47069140)
29. Donald AE, Halcox JP, Charakida M, et al. Methodological approaches to optimize reproducibility and power in clinical studies of flow-mediated dilation. J Am Coll Cardiol. 2008;51:1959-64. (Pubitemid 351636449)
30. Yeboah J, Crouse JR, Hsu FC, et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation. 2007;115:2390-7. (Pubitemid 46717961)
31. Yeboah J, Folsom AR, Burke GL,et al.: Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009, 120:502-509. This ultrasound FMD study investigated the predictive value of FMD for future cardiovascular events.
32. Yeboah J, Burke GL, Crouse JR, et al. Relationship between brachial flow-mediated dilation and carotid intima-media thickness in an elderly cohort: the Cardiovascular Health Study. Atherosclerosis. 2008;197:840-5. (Pubitemid 351417883)
33. Benjó AM, Maranhão RC, Coimbra SR, et al. Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment. Atherosclerosis. 2006;187:116-22. (Pubitemid 43817002)
34. Warnholtz A, Wild P, Ostad MA, et al. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. Atherosclerosis. 2009;204:216-21.
35. Spieker LE, Sudano I, Hürlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399-402. (Pubitemid 34263266)
36. Nieuwdorp M, Vergeer M, Bisoendial RJ, et al. Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. Diabetologia. 2008;51:1081-4.
37. Kastelein JJ, Duivenvoorden R, Deanfield J, et al.: Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation. Curr Med Res Opin. 2010 Dec 6. This is the first large, randomized, placebo-controlled ultrasound FMD trial to investigate the efficacy of the HDL-C - raising drug dalcetrapib.
38. Rudd JHF, Hyafil F, Fayad ZA. Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1009-16.
39. Zhang Z, Machac J, Helft G, et al. Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18FDG PET: a histopathological correlation. BMC Nucl Med. 2006;6:3.
40. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818-24.
41. Rominger A, Saam T, Wolpers S, et al.: 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 2009, 50:1611-1620. This study investigates the predictive value of FDG-PET for future cardiovascular events.
42. Paulmier B, Duet M, Khayat R, et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol. 2008;15:209-17. (Pubitemid 351396317)
43. Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708-11.
44. Tahara N, Kai H, Yamagishi S, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol. 2007;49:1533-9. (Pubitemid 46517964)
45. Rudd JH, Myers KS, Bansilal S, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging. 2009;2:107-15.
46. Rudd JH, Myers KS, Bansilal S, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892-6. (Pubitemid 47268746)
47. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48:1825-31. (Pubitemid 44648621)
48. Lee SJ, On YK, Lee EJ, et al. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J Nucl Med. 2008;49:1277-82.
49. Elkhawad M, Rudd JH, Sarov-Blat L, et al.: Inhibition of p38 Mitogen-Activated Protein Kinase Attenuates Vascular and Systemic Inflammation in Patients with Atherosclerosis as Assessed by 18-F Fluorodeoxyglucose PET-CT. Circulation 2010, 122:A16936. This is a randomized controlled FDG-PET trial investigating the effect of the anti-inflammatory agent p38MAPK on vessel wall inflammation.
50. Mizoguchi M, Tahara N, Nitta Y, et al.: Pioglitazone Attenuates Atherosclerotic Plaque Inflammation in Impaired Glucose Tolerance - Evaluation by Serial 18FFluorodeoxyglucose- Positron Emission Tomography/Computed Tomography. Circulation 2010, 122: A16505. This is a randomized controlled FDG-PET trial investigating the effect of pioglitazone on vessel wall inflammation.